MedTrace Logo

Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)

NCT01475149 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 33

Last updated 2017-03-27

No results posted yet for this study

Summary

This 12 week study will observe patients with and without systemic lupus erythematosus who have persistent antiphospholipid antibodies in the blood who are starting a medicine called hydroxychloroquine. It will measure if these patients have a change in a blood test called the annexin A5 resistance assay over that 12 week period.

Conditions

Interventions

OTHER

Phlebotomy

Subjects will have blood drawn at each of the 3 study visits.

Sponsors & Collaborators

  • Montefiore Medical Center

    collaborator OTHER

  • Hospital for Special Surgery, New York

    lead OTHER

Principal Investigators

  • Doruk Erkan, MD · Hospital for Special Surgery, New York

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2013-09-30
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01475149 on ClinicalTrials.gov